Los Angeles Capital Management LLC Regenxbio Inc. Transaction History

Los Angeles Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 04, 2023	SELL	$18.08 - $24.55 $267,240 - $362,873	-14,781 Reduced 43.14%	19,479 $368,000
Q4 2022 Feb 06, 2023	SELL	$20.4 - $24.73 $54,631 - $66,226	-2,678 Reduced 7.25%	34,260 $777,000
Q3 2022 Nov 02, 2022	SELL	$22.29 - $35.04 $534,558 - $840,329	-23,982 Reduced 39.37%	36,938 $976,000
Q2 2022 Aug 05, 2022	BUY	$19.35 - $35.04 $632,358 - $1.15 Million	32,680 Added 115.72%	60,920 $1.51 Million
Q1 2022 May 06, 2022	BUY	$24.62 - $34.31 $695,268 - $968,914	28,240 New	28,240 $937,000
Q4 2019 Feb 07, 2020	SELL	$34.54 - $44.87 $752,522 - $977,582	-21,787 Closed	0 $0
Q3 2019 Nov 07, 2019	SELL	$31.84 - $50.88 $159 - $254	-5 Reduced 0.02%	21,787 $776,000
Q1 2019 Apr 25, 2019	BUY	$40.82 - $62.45 $432,692 - $661,970	10,600 Added 94.71%	21,792 $1.25 Million
Q4 2018 Feb 11, 2019	BUY	$39.11 - $75.15 $8,799 - $16,908	225 Added 2.05%	11,192 $470,000
Q3 2018 Nov 05, 2018	BUY	$65.0 - $82.15 $332,800 - $420,608	5,120 Added 87.57%	10,967 $828,000
Q2 2018 Jul 31, 2018	BUY	$27.2 - $74.35 $159,038 - $434,724	5,847 New	5,847 $420,000

193

43.2M

104K

478K

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $339M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Los Angeles Capital Management LLC with notifications on news.